Alle Storys
Folgen
Keine Story von Deutsche Effecten- und Wechsel-Beteiligungsges. AG mehr verpassen.

Deutsche Effecten- und Wechsel-Beteiligungsges. AG

DEWB sells its stake in EPIDAUROS Biotechnologie AG to Clinical Data B.V.

Jena (euro adhoc) -

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
companies
DEWB AG, Jena, has sold its 75.4 percent stake in
EPIDAUROS Biotechnologie AG (Epidauros), Bernried. The buyer is 
Clinical Data B.V. based in Spankeren, the Netherlands. Clinical Data
B.V. is the European subsidiary of the Nasdaq listed company Clinical
Data Inc. with headquarters in Newton/Massachusetts, USA. The 
company, according to its own information worldwide leading supplier 
of comprehensive molecular and pharmacogenomics services as well as 
clinical diagnostics, is acquiring all the shares in Epidauros as 
part of the transaction. The contracting parties agreed on a purchase
price of 8.75 million euros in cash, the DEWB share thereof amounts 
to approx. 6.6 million euros.
Epidauros is a leading provider of pharmacogenetic-related solutions 
with a particular focus on high quality clinical genotyping. 
Moreover, the company has built a broad patent portfolio concerning 
pharmacogenetically relevant markers. Over the last years, Epidauros 
has strongly expanded its Service business and prepared the 
development of diagnostic tests in the field of personalized 
medicine. DEWB has held an interest in the company since the end of 
2000 and played an active role in assisting its development.
"This transaction is further evidence that even investments which 
were made during the highs in the markets at the end of the 
Millennium can be guided towards a successful exit with the help of 
intensive support" says Falk Nuber, member of the DEWB Management 
Board. "Even if we have not achieved our actual target return with 
Epidauros over the entire period of the investment, the exit will 
certainly make an appropriate contribution towards profits", 
continues Nuber.
The sale of Epidauros is a further step in the consistent 
implementation of the strategy to focus the investment portfolio on 
the areas of photonics and sensor systems. DEWB is currently 
evaluating further exit opportunities in order to drive forward the 
restructuring of the portfolio and in this way to concentrate on its 
technological core areas of expertise. The inflow of cash generated 
with the latest transaction is to be used for specific new 
investments within the focal area of technology.
About DEWB Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
(DEWB AG, Prime Standard, Securities No.: 804100 / ISIN: 
DE0008041005) is an investment company that specialises in young and 
established medium-sized companies. The focus of our investments is 
on strong growth companies from the areas of photonics and sensor 
systems for which we provide support through shareholders´ equity, 
expertise in corporate development and our sector network. Our 
regional focus lies in the German speaking countries (D, A, CH). 
Since 1997 we have invested more than 300 million Euros in 53 
companies and realized more than 400 million Euros through 33 exits, 
eight of which were in the form of IPOs. The company is located in 
Jena, one of the most successful technology and science regions in 
Germany, with a long tradition in the field of optical technologies 
and one of the most important European centres for Photonics.
end of announcement                               euro adhoc 23.08.2007 16:08:44

Further inquiry note:

Mirko Wäckerle
DEWB AG
Phone: +49 (0) 3641 573 3600
Fax: +49 (0) 3641 573 3610
E-Mail: ir@dewb-vc.com
www.dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / official dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse München / free trade

Weitere Storys: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
Weitere Storys: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
  • 08.08.2007 – 10:48

    bm-t and DEWB acquire majority shareholding in Zenteris

    ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. merger, acquisition and takeover Erfurt/Jena (euro adhoc) - bm-t beteiligungsmanagement thüringen gmbh (bm-t), Erfurt and Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG (DEWB), Jena took a joint stake in Zenteris GmbH (Zenteris) at the end of July 2007. In an initial round of financing, ...

  • 03.05.2007 – 10:21

    DEWB´s portfolio company NOXXON closes 37 mill. EUR financing round

    ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. investments/NOXXON Financing Round Jena/Berlin (euro adhoc) - Jena/Berlin, May 3, 2007 - DEWB´s portfolio company NOXXON Pharma AG (NOXXON), developer of mirror image oligonucleotide therapeutics termed Spiegelmers®, announced today the successful ...